The Barnstable Patriot
HYANNIS Cape Cod Hospital, in partnership with the Commonwealth of Massachusetts Department of Public Health (DPH) and the U.S. Department of Health and Human Services (HHS), announced Wednesday that it has expanded access to monoclonal antibody therapy (mAb) and will administer the treatment at a new mobile unit at the hospital.
Positioned near the COVID -19 testing site, the temporary clinic will help patients that have tested positive for COVID-19 receive immediate treatment. The promising mAb therapy has been shown to keep high-risk COVID-19 patients out of the hospital.
The temporary mAb unit is available Monday through Saturday between 1 and 6 p.m. To confirm eligibility for the treatment, patients should contact their primary care provider.
E-Mail
Houston Methodist announced today, in partnership with the U.S. Department of Health and Human Services (HHS), that it has expanded access to COVID-19 monoclonal antibody therapy (mAb) in the Greater Houston area. The promising treatment has been shown to keep high-risk COVID-19 patients out of the hospital and reduce the likelihood of progression to severe disease.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system s ability to fight off harmful pathogens such as viruses. If administered within 10 days of onset of COVID-19 symptoms, the one-time therapy is effective in neutralizing the virus and preventing symptoms from worsening. The treatment is administered through intravenous infusion, delivering medication directly into a patient s bloodstream.
People who test positive for covid-19 should ask their health care providers about receiving monoclonal antibody treatment as soon as they are diagnosed, UPMC doctors said Wednesday. “Earlier is better. It is important for high-risk patients,” said Dr. Meredith Chuk, allocation, distribution and administration lead for the federal department of
WATCH: UPMC on expanded eligibility guidelines for COVID-19 treatment Share Updated: 1:25 PM EDT May 26, 2021
WATCH: UPMC on expanded eligibility guidelines for COVID-19 treatment Share Updated: 1:25 PM EDT May 26, 2021
TRACKING THE COVID-19 VACCINE Share Updated: 1:25 PM EDT May 26, 2021 UPMC on Wednesday discussed the FDA s recent expansion of eligibility guidelines for COVID-19 monoclonal antibody treatment and how the healthcare system is making the treatment available.Watch the news briefing with UPMC and the U.S. Department of Health and Human Services: Click the video player above.Speaking at the news conference were:Dr. Meredith Chuk, HHS office of the assistant secretary for preparedness and responseTami Minnier, UPMC chief quality officerDr. Steven Evans, surgical oncologist at UPMC Hillman Cancer CenterDr. Donald Yealy, UPMC chief medical officer